Ammonium Chloride Formulations for Viral Defense
Summary
The USPTO published patent application US20260097072A1 for ammonium chloride formulations designed to support human natural defense against viral infections. The invention claims compositions and methods using lysosomotropic agents, such as ammonium chloride (NH4Cl), to prevent viral uncoating within lysosomes of infected cells. The patent names Nikolaos Tsirikos-Karapanos and Nikolaos Drakoulis as inventors.
What changed
The USPTO published patent application US20260097072A1 on April 9, 2026, covering ammonium chloride formulations and their use in supporting natural defense against viral infections. The invention discloses that administration of ammonium chloride can prevent viral uncoating within lysosomes, thereby inhibiting replication of viruses dependent on this mechanism. The application, filed October 3, 2025, under application number 19349399, claims priority to CPC classifications including A61K 33/20, A61P 31/14, and A61P 31/16.
Pharmaceutical companies and drug manufacturers should note this patent publication as it may affect research and development of antiviral treatments utilizing lysosomotropic agents. While patent applications do not create immediate compliance obligations, they establish intellectual property claims that could impact freedom-to-operate decisions for related therapeutic developments.
What to do next
- Monitor for patent issuance
- Review licensing opportunities
- Assess competitive landscape
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
FORMULATIONS OF AMMONIUM CHLORIDE TO SUPPORT HUMAN NATURAL DEFENSE AGAINST VIRUSES
Application US20260097072A1 Kind: A1 Apr 09, 2026
Inventors
Nikolaos Tsirikos-Karapanos, Nikolaos Drakoulis
Abstract
Formulations and uses thereof are provided for supporting human natural defense against viral infections as well as providing treatment for viral infections susceptible to a lysosomotropic agent. Administration of a lysosomotropic agent, such as ammonium chloride (NH4Cl), can militate against the uncoating of viruses within the lysosome of an infected cell and thereby minimize infection by viruses whose replication cycle relies upon an uncoating step in such a manner.
CPC Classifications
A61K 33/20 A61K 9/2013 A61K 9/2027 A61K 9/28 A61K 9/4866 A61K 31/593 A61P 31/14 A61P 31/16
Filing Date
2025-10-03
Application No.
19349399
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.